Key facts
- Biostate AI’s last known valuation is $65.0M (May 2025).
- It has raised $16.7M across 1 recorded rounds; the latest was Seed Round ($4.2M) in Apr 2025.
- Notable investors include Mana Ventures, Accel, Gaingels, InfoEdge Ventures, Vision Plus Capital — 23 tracked in total.
- Biostate AI has filed 1 Form D with the SEC, most recently May 2025 ($4.2M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Biostate AI
Funding rounds
1 roundsAbout Biostate AI
Developer of a biotechnology data aggregation and analysis platform intended for analyzing biopharmaceutical developments. The company's platform integrates diverse data sources, including clinical trial results, regulatory information, and scientific publications, offering tools for data visualization, trend analysis, and predictive insights, enabling researchers to assess drug development progress and make evidence-based decisions.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2023
- Employees
- 20
- Website
- biostate.ai/
- Ownership
- Privately Held (backing)
Biostate AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biostate AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biostate AI in its N-PORT filings yet. We sweep new filings monthly.